Advanced Enzyme Technologies Limited — Earnings Release 2025

May 13, 2025

May 13, 2025

BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai- 400 051

Scrip Code-540025

Trading Symbol-ADVENZYMES

Subject: Press Release Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release” dated May 13, 2025.

This is for your information and for public at large.

Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited SANJAY Digitally signed by SANJAY PRAKASH PRAKASH BASANTANI BASANTANI Date: 2025.05.13 18:48:43 +05'30' Sanjay Basantani Company Secretary and Head – Legal

Encl.: As above

==> picture [612 x 68] intentionally omitted <==

FOR IMMEDIATE RELEASE

Thane, India: Tuesday, May 13, 2025

Advanced Enzyme Technologies Limited announces Financial Results for Fourth Quarter and Year ended March 2025

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes & Probiotics, today announced their unaudited financial results for fourth quarter and year ended March 2025.

CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

(Amount in INR Mn.)	Q4 FY25 Q3 FY25 Q4 FY24 Change (Y-o-Y %) Change (Q-o-Q %)	FY25 FY24 Change (%)
Revenue EBITDA EBITDA Margin (%) PAT PAT Margin (%) EPS	1,672 1,691 1,578 6 -1 456 553 554 -18 -17 27 33 35 267 389 299 -11 -31 16 23 19 2.37 3.37 2.53 -7 -30	6,369 6,239 2 1,944 2,045 -5 31 33 1,340 1,370 -2 21 22 11.72 11.92 -2

CONSOLIDATED ANNUAL FINANCIAL REVIEW (Y-o-Y basis)

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 6,369 million in the FY25 from ₹ 6,239 million in the FY24, reported increase of 2%

Profit:

Consolidated EBITDA during FY25 stands at ₹ 1,944 million as compared to ₹ 2,045 million during FY24, declined by 5%

Margin:

EBITDA margin stands at 31%, PBT margin stands at 29% and PAT margin stands at 21% during the FY25

Financial Costs:

Financial costs stood at ₹ 36 million during FY25 as against ₹ 29 million in FY24

Depreciation and Amortization:

Profit before tax stands at ₹ 1,874 million during FY25 as against ₹ 1,879 million in FY24

Profit after tax stands at ₹ 1,340 million during FY25 as compared to ₹ 1,370 million during the FY24, declined by 2%

Depreciation and Amortization charge for the FY25 is ₹ 366 million as compared to ₹ 352 million in FY24

Earnings Per Share:

Earnings Per Share during FY25 stands at ₹ 11.72 as compared to ₹ 11.92 in FY24

==> picture [612 x 11] intentionally omitted <==

1 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

Segmental Revenue:
(Amount in INR Mn.)	FY25 FY24Change (%)
Human Nutrition Animal Nutrition Bio-Processing Specialized Manufacturing	4,053 4,185 -3 760 677 12 1,018 962 6 539 415 30

The total revenue from operations grew by 2% on y-o-y basis

The human nutrition segment underperformed by 3% to ₹ 4,053 million in FY25 as compared to ₹ 4,185 million in FY24

The Animal nutrition outperformed by 12% to ₹ 760 million in FY25 as against ₹ 677 million in FY24

==> picture [196 x 173] intentionally omitted <==

----- Start of picture text -----

8%
Human Nutrition
16%
Animal Nutrition
Bio-Processing
12%
64%
Specialized
Manufacturing
----- End of picture text -----

The Bio-Processing segment grew by 6% during the year, it accounted for ₹ 1,018 million in FY25 as compared to ₹ 962 million in FY24. In this segment, food business contributed 13% and stood at ₹ 810 million, delivering growth of 4% while the Non-Food business contributed 3% and stood at ₹ 208 million, grew by 12%, during FY25

The Specialized manufacturing segment contributed 8% to the revenue stream. This segment grew by 30% to add ₹ 539 million to the revenue during FY25

Geographical Revenue:

==> picture [250 x 146] intentionally omitted <==

----- Start of picture text -----

3%
9%
5% India
Americas
46%
Europe
Asia (ex-India)
37% Rest of the world
----- End of picture text -----

The total revenue comprises of International sales amounting to ₹ 3,464 million in FY25 as compared to ₹ 3,133 million in FY24, growth of 11%. The revenue risen by 13% in Americas, 29% in Asia (ex-India) while declined by 16% in Europe and 9% in rest of the world

Domestic sales accounted for ₹ 2,905 million in FY25 as compared to ₹ 3,106 million in FY24, decrease of 6%

The domestic sales constituted about 46% of the revenue from operations during FY25 as compared to 50% during FY24. International sales were 54% of

revenue from operations as compared to 50% during FY24

==> picture [612 x 11] intentionally omitted <==

2 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations: Revenue from operations on consolidated basis increased to ₹ 1,672 million in the Q4 FY25 from ₹ 1,578 million in the Q4 FY24, a growth of 6%

Profit:

Consolidated EBITDA during Q4 FY25 stands at ₹ 456 million as compared to ₹ 554 million during Q4 FY24, declined by 18%

Margin:

EBITDA margin stands at 27%, PBT margin stands at 26% and PAT margin stands at 16% during the quarter

Financial Costs:

Financial costs remained unchanged at ₹ 8 million during Q4 FY25 as compared to Q4 FY24

Depreciation and Amortization:

Profit before tax stands at ₹ 435 million during Q4 FY25 as against ₹ 396 million in Q4 FY24, increase of 9%

Profit after tax de-grew by 11% and stands at ₹ 267 million during Q4 FY25 as compared to ₹ 299 million during the Q4 FY24

Depreciation and Amortization charge for the Q4 FY25 stood at ₹ 101 million as compared to ₹ 93 million same quarter previous year

Earnings Per Share:

Earnings Per Share during Q4 FY25 stands at ₹ 2.37 as compared to ₹ 2.53 in Q4 FY24

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

Segmental Revenue:
(Amount in INR Mn.)	Q4 FY25 Q4 FY24 Change (%)
Human Nutrition Animal Nutrition Bio-Processing Specialized Manufacturing	1,031 1,024 1 209 185 13 278 258 8 154 111 39

The total revenue from operations grew by 6% on y-o-y basis

The revenue from human nutrition segment increased by 1% to ₹ 1,031 million in Q4 FY25 as compared to ₹ 1,024 million in Q4 FY24

The Animal nutrition delivered a growth of 13% to ₹ 209 million in Q4 FY25 as against ₹ 185 million in Q4 FY24

==> picture [196 x 173] intentionally omitted <==

----- Start of picture text -----

9%
Human Nutrition
17%
Animal Nutrition
Bio-Processing
12% 62%
Specialized
Manufacturing
----- End of picture text -----

the quarter, it accounted for ₹ 278 million in Q4 FY25 as compared to ₹ 258 million in Q4 FY24. In this segment, food business grew by 16% to ₹ 230 million on y-o-y basis during Q4 FY25. The NonFood business de-grew by 21% to stood at ₹ 48 million during the quarter

The Specialized manufacturing segment contributed 9% in the pie which is around ₹ 154 million to the revenue during the quarter, an increase of 39% on y-o-y basis

The Bio-Processing segment grew by 8% during

==> picture [612 x 11] intentionally omitted <==

3 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

Geographical Revenue:

==> picture [250 x 147] intentionally omitted <==

----- Start of picture text -----

2%
11%
India
6%
Americas
42%
Europe
Asia (ex-India)
Rest of the world
39%
----- End of picture text -----

The total revenue comprises of International sales amounting to ₹ 968 million in Q4 FY25 as

compared to ₹ 804 million in Q4 FY24, an increase of 20%. The revenue increased by 22% in Americas, 48% in Asia (ex-India) and 116% in the rest of the world while there is de-growth of 25% in Europe

Domestic sales accounted for ₹ 704 million in Q4 FY25 as compared to ₹ 774 million in Q4 FY24, a de-growth of 9%

The domestic sales constituted about 42% of revenue from operations during Q4 FY25 as compared to 49% during Q4 FY24. International sales were 58% of revenue from operations during Q4 FY25 as compared to 51% during Q4 FY24

==> picture [612 x 11] intentionally omitted <==

4 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

Revenue from Operations:

Revenue from operations on consolidated basis increased to ₹ 1,672 million in the Q4 FY25 from ₹ 1,691 million in the Q3 FY25, a de-growth of 1%

Profit:

Consolidated EBITDA during Q4 FY25 stands at ₹ 456 million as compared to ₹ 553 million during Q3 FY25, declined by 17%

Profit before tax stands at ₹ 435 million during Q4 FY25 as against ₹ 530 million in Q3 FY25, declined by 18%

Profit after tax de-grew by 31% and stands at

₹ 267 million during Q4 FY25 as compared to ₹ 389 million during the Q3 FY25

Financial Costs:

Financial costs stood at ₹ 8 million during Q4 FY25 as compared to ₹ 9 million during Q3 FY25

Depreciation and Amortization:

Depreciation and Amortization charge for the Q4 FY25 is ₹ 101 million as compared to ₹ 90 million in the last quarter

Earnings Per Share:

Earnings Per Share during Q4 FY25 stands at ₹ 2.37 as compared to ₹ 3.37 in Q3 FY25

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q4 FY25 Q3 FY25 Change (%)
Human Nutrition Animal Nutrition Bio-Processing Specialized Manufacturing	1,031 1,018 1 209 197 6 278 321 -13 154 154 0

The human nutrition segment increased by 1% to ₹ 1,031 million in Q4 FY25 as compared to ₹ 1,018 million in Q3 FY25

The Animal nutrition grew by 6% to ₹ 209 million in Q4 FY25 as against ₹ 197 million in Q3 FY25

The Bio-Processing segment underperformed by 13% during the quarter, it accounted ₹ 278 million

in Q4 FY25 as compared to ₹ 321 million in Q3 FY25. In this segment, the food and non-food business de-grew by 14% to ₹ 230 million, and 10% to ₹ 48 million respectively, during the quarter in comparison to Q3 FY25

The Specialized manufacturing segment remain unchanged at ₹ 154 million in Q4 FY25 in comparison to last quarter

Geographical Revenue:

The total revenue comprises of International sales amounting to ₹ 968 million in Q4 FY25 as compared to ₹ 932 million in Q3 FY25, it grew by 4%. The revenue grew by 15% in Americas, while it de-grew by 3% in Europe, 8% in Asia (ex-India), 45% in rest of the world

Domestic sales accounted for ₹ 704 million in

Q4 FY25 as compared to ₹ 759 million in Q3 FY25, declined by 7%

The domestic sales constituted about 42% of revenue from operations during Q4 FY25 as compared to 45% during Q3 FY25. International sales were 58% of revenue from operations during Q4 FY25 as compared to 55% during Q3 FY25

==> picture [612 x 11] intentionally omitted <==

5 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

OUTLOOK 2025-26

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

Human Nutrition:

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

Bio Catalysis:

The Company has achieved notable progress in developing biocatalases for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

Baking:

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

R&D:

Animal Nutrition:

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

Probiotics:

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

Inorganic expansion:

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.

==> picture [612 x 11] intentionally omitted <==

6 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 14[th] May 2025, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company’s website, www.advancedenzymes.com

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: +91 22 6280 1403 / +91 22 7115 8304

Pre-registration link

For further information, please contact:

Ronak Saraf

Investor Relations ir@advancedenzymes.com

CORPORATE INFORMATION : Advanced Enzyme Technologies Limited Regd. Office: 5[th] Floor, ‘A’ Wing, Sun Magnetica, Louiswadi, Thane (W) ‐400 604, Maharashtra, India Tel.: +91 22 41703200 Fax: +91-22 25835159 Website: www.advancedenzymes.com CIN No: L24200MH1989PLC051018

==> picture [612 x 11] intentionally omitted <==

7 | P a g e

WWW.ADVANCEDENZYMES.COM

==> picture [612 x 68] intentionally omitted <==

ABOUT ADVANCED ENZYME TECHNOLOGIES LIMITED

Advanced Enzyme Technologies Limited, incorporated in 1989, is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Equipped with state-of-the-art 9 manufacturing facilities and 7 research & development locations across India, Germany and US, Advanced Enzymes exports to 45+ countries across 6 continents, and provides customized & effective enzyme solutions coupled with the best in technical advice & superior service.

Advanced Enzymes has received the Bio-Excellence award for being the Best Industrial Biotech Company at Bangalore India Bio in 2010 as well as 2014. In 2013, Advanced Enzymes has also been recognised by Inc. India, as one of the top 500 fastest-growing mid-sized companies in India, Excellence in R&D at UBM India Pharma Awards 2018. Advanced Enzymes has also been recipient of the Emerging India Award in 2010, in the Life Sciences category, by CNBC TV18 and ICICI Bank. Advanced Enzymes has also been awarded for Best IPO at IR Society Awards 2017, by Investor Relation Society of India in association with BSE, KPMG India and Bloomberg.

FORWARD‐LOOKING STATEMENTS

This press release may contain forward‐looking statements with respect to Advanced Enzyme Technologies’ future (financial) performance and position. Such statements are based on current expectations, estimates and information currently available to the company.

Advanced Enzyme Technologies Limited cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. The company has no obligation to update the statements contained in this press release, unless required by law.

==> picture [612 x 11] intentionally omitted <==

8 | P a g e

WWW.ADVANCEDENZYMES.COM